Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?

por Boone, Niels Willem, van Leeuwen, Roelof Wouter Frederik
Publicado 2012

How to select a best-value biological medicine? A practical model to support hospital pharmacists

por Barbier, Liese, Vandenplas, Yannick, Boone, Niels, Huys, Isabelle, Janknegt, Rob, Vulto, Arnold G
Publicado 2022

Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)

por Boone, Niels W., Teeuwisse, Patty, van der Kuy, Paul-Hugo, Janknegt, Rob, Landewé, Robert B. M.
Publicado 2015

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time

por Boone, Niels W., Sepriano, Alexandre, van der Kuy, Paul-Hugo, Janknegt, Rob, Peeters, Ralph, Landewé, Robert B. M.
Publicado 2019

Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice

por Boone, Niels W, Sepriano, Alexandre, van der Kuy, Paul-Hugo, Janknegt, Rob, Peeters, Ralph, Landewé, Robert B M
Publicado 2019